Alvarez & Marsal Expands Its Capital Markets & Accounting Advisory Senior Talent Globally
Leading global professional services firm Alvarez & Marsal (A&M) announced the appointment of Stockholm-based Annika Melin Jakobsson and New York-based Patricia Alonso de la Fuente as Global Transaction Advisory Group (TAG) Managing Directors within its Capital Markets & Accounting Advisory (CMAA) practice. Ms. Melin Jakobsson will develop A&M’s CMAA offering in the Nordics and EMEA. Ms. Alonso de la Fuente will support CMAA in the US, Spain and its continued Latin American (LatAm) expansion.
Paul Aversano, Global Practice Leader of A&M’s Global Transaction Advisory Group, said, “Building our CMAA offering in the Nordics and EMEA while expanding it across LatAm and Spanish speaking countries enhances our independent capital markets and advisory accounting advice capabilities for private equity (PE) and multinational corporate clients seeking transaction support. Following on CMAA Managing Director Ayres Moura’s recent hire, Annika’s and Patricia’s joining aligns with our strategic talent, capabilities, and geographic growth plan.”
Ms. Melin Jakobsson, A&M’s Nordic CMAA practice Leader who will support this offering across EMEA, specializes in initial public offerings (IPO), carve-outs, capital markets transactions, corporate governance, risk, compliance, and all mergers and acquisitions (M&A) lifecycle aspects. She advises board and management teams, in listed and non-listed companies, and has led national and international large- mid- and small cap IPOs and capital markets transactions. Ms. Melin Jakobsson ensures clients’ IPO readiness, and once listed, their alignment with capital markets’ governance, risk and compliance and financial reporting requirements.
Ms. Alonso de la Fuente’s global mindset and local expertise crisscrosses her extensive cross-border and cross-functional market transaction experience. She focuses on IPOs, acquisitions, divestitures, international financial reporting standards (IFRS), US generally accepted accounting principles (GAAP) conversions and complex technical accounting matters. Additionally, she has led complex, cross-functional M&A and IPO projects and developed holistic solutions for clients across diverse sectors in the Americas and Europe.
Phil Mitchell, EMEA TAG Practice Co-Leader, noted, “A&M’s freedom from audit conflicts and integrated platform enables independent capital markets and accounting advice that maximizes value for PE and corporate clients. Annika’s and Patricia’s combined expertise solidifies our global CMAA offering and elevates our exit readiness capabilities.”
Previously, Ms. Melin Jakobsson served as Managing Partner for EY’s Nordic Capital Markets group and Managing Partner for KPMG’s Deal Advisory Capital Markets Group in Sweden. While at KPMG, she also served as a member of its board of directors.
Prior to joining A&M, Ms. Alonso de la Fuente served with KPMG, most recently as Partner in Deal Advisory in New York, along with leading that firm’s Capital Markets and Accounting Advisory Services US-LatAm corridor.
Mses. Melin Jakobsson and Alonso de la Fuente, said, “Capital markets are part of the transaction lifecycle. With tailored teams to meet needs and demands, A&M’s business model supports clients wherever we are in that cycle. Across the transaction spectrum, from aligning IPO readiness to planning exits, now is the time for corporates and PE to prepare.”
Ms. Melin Jakobsson earned a master’s degree in law from Uppsala University and has been part of the Swedish Nasdaq Listing Auditor’s team for 10+ years. She has been engaged as a capital market specialist by the Swedish Institute for the Accountancy Profession, Accountancy Europe and the Centre for Business and Policy Studies.
Ms. Alonso de la Fuente holds a bachelor’s degree in business administration from Complutense University, Madrid, and Leeds, United Kingdom.
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 9,000 people across six continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what is really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
About Alvarez & Marsal Global Transaction Advisory Group
A&M’s Global Transaction Advisory Group provides investors and lenders the answers needed to get the deal done. We combine our firm’s deep operational, industry and functional resources with Big Four-quality financial accounting and tax expertise to assess key deal drivers and focus on the root cause of any critical deal issues. As the largest transaction advisory practice outside the Big Four, our global integrated teams help private equity, sovereign wealth funds, family offices and hedge funds as well as corporate acquirers unlock value across the investment lifecycle.
The firm’s Global Transaction Advisory Group includes over 950 professionals in 37 offices worldwide. Our global team has extensive industry knowledge across multiple sectors and is free from audit-based conflicts of interests.
To learn more, visit: AlvarezandMarsal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122439270/en/
Contact information
Sandra Sokoloff, Senior Director of Global Public Relations
Alvarez & Marsal, +1 212-763-9853
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
